Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.
about
A limited sampling strategy for estimation of the area under the curve (0 to 8 hours) of mycophenolic acid administered three times daily to liver transplant recipientsIntensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial.Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis.Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients.Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials NetworkProphylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors.Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation.Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation.
P2860
Q34577357-2A5FF118-53C7-4D6F-984E-5E94999E982EQ35533371-CA429BE7-DFFA-4104-9FD9-3971AB5C0A6AQ36623408-DE6F1426-3299-43A0-A7CC-C95F129C4092Q36629233-CFBF0465-3F00-4122-BB6C-1584BDE41EEAQ36777485-0D289EE0-61D4-4EB9-91FF-4965E1DF3448Q36821646-8A85DD64-6258-41EF-B2C6-F44C3E8D8B12Q37201939-38F1CA9D-579D-4B8C-B5BE-BCD476CFEE21Q38010596-753640EB-9503-4F49-AA56-18BBE12980BDQ38262916-1BD26876-40F6-463E-89C5-817D5DD4443FQ38817096-12834348-BD07-42A3-A3B8-62BDA4704784Q42149848-07F1A689-4D77-4DF8-A31B-87D1B824B3DEQ43283506-1F32CEC6-0BE9-4068-99D6-F01B737A95BEQ48253938-6EC6C25C-A06F-40E1-9CD3-669C4E15A092Q53126891-97413F8D-C7DC-46BB-AD8B-B60C91EE4952
P2860
Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comparison of two mycophenolat ...... opoietic cell transplantation.
@ast
Comparison of two mycophenolat ...... opoietic cell transplantation.
@en
type
label
Comparison of two mycophenolat ...... opoietic cell transplantation.
@ast
Comparison of two mycophenolat ...... opoietic cell transplantation.
@en
prefLabel
Comparison of two mycophenolat ...... opoietic cell transplantation.
@ast
Comparison of two mycophenolat ...... opoietic cell transplantation.
@en
P2093
P2860
P356
P1476
Comparison of two mycophenolat ...... opoietic cell transplantation.
@en
P2093
C Brunstein
C Jennissen
D Weisdorf
J Long-Boyle
J Rogosheske
P Jacobson
S F El-Massah
P2860
P2888
P304
P356
10.1038/BMT.2008.428
P407
P577
2009-01-19T00:00:00Z
P5875
P6179
1024524799